Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes
Abstract
:1. Introduction
2. Materials and Methods
2.1. Sample Origin
2.2. Sample Preparation and Analysis
2.2.1. Chemicals and Standards
2.2.2. Sample Preparation for MGO Assay
2.2.3. MGO Determination by UHPLC-ESI-QqTOF-MS
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Available online: https://www.idf.org/metabolic_syndrome (accessed on 1 July 2023).
- Tuomilehto, J.; Wolf, E. Primary prevention of diabetes mellitus. Diabetes Care 1987, 10, 238–248. [Google Scholar] [CrossRef] [PubMed]
- Roberts, S.; Barry, E.; Craig, D.; Airoldi, M.; Bevan, G.; Greenhalgh, T. Preventing type 2 diabetes: Systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open 2017, 7, e017184. [Google Scholar] [CrossRef] [PubMed]
- Aroda, V.R.; Knowler, W.C.; Crandall, J.P.; Perreault, L.; Edelstein, S.L.; Jeffries, S.L.; Molitch, M.E.; Pi-Sunyer, X.; Darwin, C.; Heckman-Stoddard, B.M.; et al. Metformin for diabetes prevention: Insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 2017, 60, 1601–1611. [Google Scholar] [CrossRef] [PubMed]
- Zhou, X.; Siegel, K.R.; Ng, B.P.; Jawanda, S.; Proia, K.K.; Zhang, X.; Albright, A.L.; Zhang, P. Cost-effectiveness of diabetes prevention interventions targeting high-risk individuals and whole populations: A systematic review. Diabetes Care 2020, 43, 1593–1616. [Google Scholar] [CrossRef] [PubMed]
- American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2019. Diabetes Care 2019, 42 (Suppl. S1), S13–S28. [Google Scholar] [CrossRef] [PubMed]
- Nikolaos, P.; Ziegler, D. Prediabetic neuropathy: Does it exist? Curr. Diab. Rep. 2012, 12, 376–383. [Google Scholar]
- Brings, S.; Fleming, T.; Freichel, M.; Muckenthaler, M.U.; Herzig, S.; Nawroth, P.P. Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. Int. J. Mol. Sci. 2017, 18, 984. [Google Scholar] [CrossRef] [PubMed]
- Mortera, R.R.; Bains, Y.; Gugliucci, A. Fructose at the crossroads of the metabolic syndrome and obesity epidemics. Front. Biosci. (Landmark Ed.) 2019, 24, 186–211. [Google Scholar]
- Thornalley, P.J.; Yurek-George, A.; Argirov, O.K. Kinetics and mechanism of the reaction of aminoguanidine with the oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem. Pharmacol. 2000, 60, 55–65. [Google Scholar] [CrossRef]
- LO, T.W.; Westwood, M.E.; Mclellan, A.C.; Selwood, T.; Thornalley, P.J. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N -acetylarginine, N-acetylcysteine, and N-acetyllysine, and bovine serum albumin. J. Biol. Chem. 1994, 269, 32299–32305. [Google Scholar] [CrossRef]
- Smuda, M.; Glomb, M.A. Maillard degradation pathways of vitamin C. Angew. Chem. Int. Ed. Engl. 2013, 52, 4887–4891. [Google Scholar] [CrossRef] [PubMed]
- Kalapos, M.P. Where does plasma methylglyoxal originate from? Diabetes Res. Clin. Pract. 2013, 99, 260–271. [Google Scholar] [CrossRef] [PubMed]
- Hanssen, N.; Scheijen, J.; Houben, A.; van de Waarenburg, M.; Berendschot, T.; Webers, C.; Reesink, K.; van Greevenbroek, M.; van der Kallen, C.; Schaper, N.; et al. Fasting and post-oral-glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in individuals with and without (pre)diabetes: The Maastricht Study. Diabetes Metab. 2021, 47, 101148. [Google Scholar] [CrossRef]
- Hanssen, N.M.J.; Engelen, L.; Ferreira, I.; Scheijen, J.L.J.M.; Huijberts, M.S.; van Greevenbroek, M.M.J.; van der Kallen, C.J.H.; Dekker, J.M.; Nijpels, G.; Stehouwer, C.D.A.; et al. Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine. Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: The Hoorn and CODAM studies. J. Clin. Endocrinol. Metab. 2013, 98, E1369–E1373. [Google Scholar] [CrossRef] [PubMed]
- Hanssen, N.M.; Beulens, J.W.; van Dieren, S.; Scheijen, J.L.; van der A, D.L.; Spijkerman, A.M.; van der Schouw, Y.T.; Stehouwer, C.D.; Schalkwijk, C.G. Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: A case-cohort study with a median follow-up of 10 years (EPIC-NL). Diabetes 2015, 64, 257–265. [Google Scholar] [CrossRef] [PubMed]
- The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); The European Association for the Study of Diabetes (EASD). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020, 41, 255–323. [Google Scholar] [CrossRef] [PubMed]
- Sutkowska, E.; Fortuna, P.; Kałuża, B.; Sutkowska, K.; Wiśniewski, J.; Gamian, A. Metformin has no impact on nitric oxide production in patients with pre-diabetes. Biomed. Pharmacother. 2021, 140, 111773. [Google Scholar] [CrossRef]
- Gensberger-Reigl, S.; Huppert, J.; Pischetsrieder, M. Quantification of reactive carbonyl compounds in icodextrin-based peritoneal dialysis fluids by combined UHPLC DAD and -MS/MS detection. J. Pharm. Biomed. Anal. 2016, 118, 132–138. [Google Scholar] [CrossRef]
- Henning, C.; Liehr, K.; Girndt, M.; Ulrich, C.; Glomb, M.A. Extending the spectrum of alpha-dicarbonyl compounds in vivo. J. Biol. Chem. 2014, 289, 28676–28688. [Google Scholar] [CrossRef]
- Rabbani, N.; Thornalley, P.J. Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nat. Protoc. 2014, 9, 1969–1979. [Google Scholar] [CrossRef]
- Scheijen, J.L.; Schalkwijk, C.G. Quantification of glyoxal, methylglyoxal and 3- deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: Evaluation of blood specimen. Clin. Chem. Lab. Med. 2014, 52, 85–91. [Google Scholar] [CrossRef] [PubMed]
- Hanssen, N.M.; Scheijen, J.L.; Jorsal, A.; Parving, H.-H.; Tarnow, L.; Rossing, P.; Stehouwer, C.D.; Schalkwijk, C.G. Higher plasma methylglyoxal levels are associated with incident cardiovascular disease in individuals with type 1 diabetes: A 12-year follow-up study. Diabetes 2017, 66, 2278–2283. [Google Scholar] [CrossRef] [PubMed]
- Hanssen, N.M.; Westerink, J.; Scheijen, J.L.; van der Graaf, Y.; Stehouwer, C.D.; Schalkwijk, C.G.; Algra, A.; Grobbee, R.D.; Rutten, G.E.; Visseren, F.L.; et al. Higher plasma methylglyoxal levels are associated with incident cardiovascular disease and mortality in individuals with type 2 diabetes. Diabetes Care 2018, 41, 1689–1695. [Google Scholar] [CrossRef] [PubMed]
- Nin, J.W.; Jorsal, A.; Ferreira, I.; Schalkwijk, C.G.; Prins, M.H.; Parving, H.H.; Tarnow, J.; Rossing, P.; Stehouwer, C.D. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes Care 2011, 34, 442–447. [Google Scholar] [CrossRef] [PubMed]
- Lu, J.; Randell, E.; Han, Y.; Adeli, K.; Krahn, J.; Meng, Q.H. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin. Biochem. 2011, 44, 307–311. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Meng, Q.H.; Gordon, J.R.; Khandwala, H.; Wu, L. Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. Clin. Biochem. 2007, 40, 1232–1239. [Google Scholar] [CrossRef] [PubMed]
- Sabbatinelli, J.; Castiglione, S.; Macrì, F.; Giuliani, A.; Ramini, D.; Vinci, M.C.; Tortato, E.; Bonfigli, A.R.; Olivieri, F.; Raucci, A. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: A retrospective cohort study. Cardiovasc. Diabetol. 2022, 21, 95. [Google Scholar] [CrossRef] [PubMed]
- Jensen, T.M.; Vistisen, D.; Fleming, T.; Nawroth, P.P.; Rossing, P.; Jørgensen, M.E.; Lauritzen, T.; Sandbaek, A.; Witte, D.R. Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus. Diabet. Med. 2016, 33, 1625–1631. [Google Scholar] [CrossRef]
- Araszkiewicz, A.; Bandurska-Stankiewicz, E.; Borys, S.; Budzyński, A.; Cyganek, K.; Cypryk, K.; Czech, A.; Czupryniak, L.; Drzewoski, J.; Dzida, G.; et al. Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Clin. Diab. 2021, 10, 1–113. [Google Scholar]
- Hanssen, N.M.; Teraa, M.; Scheijen, J.L.; Van de Waarenburg, M.; Gremmels, H.; Stehouwer, C.D.; Verhaar, M.C.; Schalkwijk, C.G. Plasma methylglyoxal levels are associated with amputations and mortality in severe limb ischemia patients with and without diabetes. Diabetes Care 2021, 44, 157–163. [Google Scholar] [CrossRef]
- Baye, E.; Mark, A.B.; Poulsen, M.W.; Andersen, J.M.; O Dragsted, L.; Bügel, S.G.; de Courten, B. Associations between urinary advanced glycation end products and cardiometabolic parameters in metabolically healthy obese women. J. Clin. Med. 2019, 8, 1008. [Google Scholar] [CrossRef] [PubMed]
- Xue, M.; Weickert, M.O.; Qureshi, S.; Kandala, N.-B.; Anwar, A.; Waldron, M.; Shafie, A.; Messenger, D.; Fowler, M.; Jenkins, G.; et al. Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation. Diabetes 2016, 65, 2282–2294. [Google Scholar] [CrossRef] [PubMed]
- Baba, S.P.; Barski, O.A.; Ahmed, Y.; O’Toole, T.E.; Conklin, D.J.; Bhatnagar, A.; Srivastava, S. Reductive metabolism of AGE precursors: A metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes 2009, 58, 2486–2497. [Google Scholar] [CrossRef] [PubMed]
- Beisswenger, P.J.; Howell, S.K.; Touchette, A.D.; Lal, S.; Szwergold, B.S. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999, 48, 198–202. [Google Scholar] [CrossRef] [PubMed]
- Ruggiero-Lopez, D.; Lecomte, M.; Moinet, G.; Patereau, G.; Lagarde, M.; Wiernsperger, N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 1999, 58, 1765–1773. [Google Scholar] [CrossRef] [PubMed]
- Kender, Z.; Fleming, T.; Kopf, S.; Torzsa, P.; Grolmusz, V.; Herzig, S.; Schleicher, E.; Rácz, K.; Reismann, P.; Nawroth, P.P. Effect of metformin on methylglyoxal metabolism in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2014, 122, 316–319. [Google Scholar] [CrossRef] [PubMed]
- Hess, A.M.; Sullivan, D.L. Metformin for prevention of type 2 diabetes. Ann. Pharmacother. 2004, 38, 1283–1285. [Google Scholar] [CrossRef] [PubMed]
- Forbes, J.M.; Yee, L.T.L.; Thallas, V.; Lassila, M.; Candido, R.; Jandeleit-Dahm, K.A.; Thomas, M.C.; Burns, W.C.; Deemer, E.K.; Thorpe, S.R.; et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004, 53, 1813–1823. [Google Scholar] [CrossRef] [PubMed]
- Watson, A.M.D.; Soro-Paavonen, A.; Sheehy, K.; Li, J.; Calkin, A.C.; Koitka, A.; Rajan, S.N.; Brasacchio, D.; Allen, T.J.; Cooper, M.E.; et al. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2011, 54, 681–689. [Google Scholar] [CrossRef]
- Schalkwijk, C.G.; Stehouwer, C.D.A. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other AGE-related diseases. Physiol. Rev. 2020, 100, 407–461. [Google Scholar] [CrossRef]
- Rabbani, N.; Chittari, M.V.; Bodmer, C.W.; Zehnder, D.; Ceriello, A.; Thornalley, P.J. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010, 59, 1038–1045. [Google Scholar] [CrossRef] [PubMed]
- Rabbani, N.; Godfrey, L.; Xue, M.; Shaheen, F.; Geoffrion, M.; Milne, R.; Thornalley, P.J. Glycation of LDL by methylglyoxal increases arterial atherogenicity: A possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 2011, 60, 1973–1980. [Google Scholar] [CrossRef] [PubMed]
- Schalkwijk, C.G.; Vermeer, M.A.; Stehouwer, C.D.; Koppele, J.T.; Princen, H.M.; van Hinsbergh, V.W. Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. Biochem. Biophys. Acta 1998, 1394, 187–198. [Google Scholar] [CrossRef] [PubMed]
- Murphy, C.; Deplazes, E.; Cranfield, C.G.; Garcia, A. The role of structure and biophysical properties in the pleiotropic effects of statins. Int. J. Mol. Sci. 2020, 21, 8745. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Q.; Liao, J.K. Statins and cardiovascular diseases: From cholesterol lowering to pleiotropy. Curr. Pharm. Des. 2009, 15, 467–478. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.Y.; Liu, P.Y.; Liao, J.K. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends. Mol. Med. 2008, 14, 37–44. [Google Scholar] [CrossRef] [PubMed]
- Lankin, V.Z.; Tikhaze, A.K.; Kapel’ko, V.I.; Shepel’kova, G.S.; Shumaev, K.B.; Panasenko, O.M.; Konovalova, G.G.; Belenkov, Y.N. Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative and carbonyl stress. Biochemistry 2007, 72, 1081–1090. [Google Scholar] [CrossRef] [PubMed]
- Sourris, K.C.; Watson, A.; Jandeleit-Dahm, K. Inhibitors of advanced glycation end product (AGE) formation and accumulation. Handb. Exp. Pharmacol. 2021, 264, 395–423. [Google Scholar]
Variable | pre-DM, N = 31 | Control, N = 11 | p | ||
---|---|---|---|---|---|
Mean | ±SD | Mean | ±SD | ||
age (years) | 53.65 | 8.35 | 49.91 | 8.37 | ns |
body weight (kg) | 93.71 | 14.35 | 80.82 | 20.64 | 0.0284 |
BMI (kg/m2) | 31.40 | 6.07 | 26.99 | 5.43 | 0.04 |
creatinine (mg/dL) | 0.84 | 0.17 | 0.73 | 0.03 | ns |
ALT (U/L) | 30.3 | 15.95 | 19.11 | 12.06 | ns |
TC (mg/dL) | 197 | 42.64 | 201 | 27.47 | ns |
TG (mg/dL) | 130.24 | 59.98 | 137.09 | 49.20 | ns |
HDL-C (mg/dL) | 52.64 | 15.93 | 57.91 | 16.82 | ns |
LDL-C (mg/dL) | 117.38 | 27.21 | 114.83 | 20.76 | ns |
FG (mg/dl) | 108.85 | 9.44 | 88.81 | 4.44 | <0.001 |
HbA1c (%) | 5.76 | 0.59 | 5.27 | 0.35 | ns |
Variable | pre-DM, N = 31 | Control, N = 11 | p | ||
---|---|---|---|---|---|
YES, n | YES, % | YES, n | YES, % | ||
Sex (woman) | 12 | 38.71 | 6 | 54.55 | ns |
Nicotinism | 7 | 22.58 | 2 | 18.18 | ns |
Hypertension | 17 | 54.84 | 3 | 27.27 | ns |
Fatty liver | 18 | 64.29 | 1 | 9.09 | 0.001 |
Family history for DM | 12 | 38.71 | 3 | 27.27 | ns |
ACEI/ARB | 10 | 33.33 | 3 | 27.27 | ns |
Beta-blockers | 8 | 26.67 | 2 | 18.18 | ns |
Calcium-blockers | 3 | 10 | 0 | 0 | ns |
Diuretics | 4 | 13.33 | 0 | 0 | ns |
Statins | 10 | 32.26 | 0 | 0 | 0.03 |
Fibrates | 1 | 3.23 | 0 | 0 | ns |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sutkowska, E.; Fecka, I.; Marciniak, D.; Bednarska, K.; Sutkowska, M.; Hap, K. Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes. Biomedicines 2023, 11, 2968. https://doi.org/10.3390/biomedicines11112968
Sutkowska E, Fecka I, Marciniak D, Bednarska K, Sutkowska M, Hap K. Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes. Biomedicines. 2023; 11(11):2968. https://doi.org/10.3390/biomedicines11112968
Chicago/Turabian StyleSutkowska, Edyta, Izabela Fecka, Dominik Marciniak, Katarzyna Bednarska, Magdalena Sutkowska, and Katarzyna Hap. 2023. "Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes" Biomedicines 11, no. 11: 2968. https://doi.org/10.3390/biomedicines11112968